Vaxcyte, Inc (PCVX) September 105 puts active as share price up 37%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Vaxcyte (PCVX) PT Raised to $140 at BofA Securities
September 4, 2024 5:27 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Vaxcyte (NASDAQ: PCVX) to $140.00 (from $101.00) while maintaining a Buy rating.
The analyst comments "Vaxcyte shares are up (+35%) on announced positive Ph1/2 results for VAX-31, a pneumococcal vaccine tested in... More
TD Cowen Reiterates Buy Rating on Vaxcyte (PCVX)
September 3, 2024 4:10 PM EDTTD Cowen analyst Tara Bancroft reiterated a Buy rating on Vaxcyte (NASDAQ: PCVX).
The analyst comments "Recall that VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) developed to expand coverage to over 95% of circulating invasive pneumococcal disease (IPD) in the US (and 98% in the EU). For reference, Pfizer's Prevnar 20 (PCV20, 20-valent and currently the market leader) only covers 52%, and Merck's more recently approved V116 (PCV21; 21-valent and recommended on parity with PCV20 here) only covers 83%. In the... More
